Corona Remedies IPO Date, Review, Price, Allotment Details IPO
Corona Remedies IPO Summary
IPO Open Date: 08 Dec 2025
IPO Close Date: 10 Dec 2025
Price Band: ₹1008 to ₹1062 Per Share
Issue Size: Approx ₹655.37 Crores
Listing Exchange: BSE NSE
Website: https://www.coronaremedies.com/
Corona Remedies IPO Overview
Corona Remedies IPO open date is December 8, 2025 and the IPO will close on December 10, 2025. Corona Remedies IPO is a Book Built Issue. The company to raise around ₹655.37 crores via IPO that comprises fresh issue of ₹[.] crores and offer for sale up to 61,71,101 equity shares with face value of ₹10 each.
Corona Remedies IPO price band is ₹1008 to ₹1062 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Corona Remedies IPO to list on BSE, NSE on December 15, 2025. The allotment of Corona Remedies IPO date is December 11, 2025.
The company reported revenue of ₹1,202.35 crores in 2025 against ₹1,020.93 crores in 2024. The company reported profit of ₹149.43 crores in 2025 against profit of ₹90.50 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.
Corona Remedies IPO Details
| Company Name | Corona Remedies Ltd |
| IPO Open Date | 08 Dec 2025 |
| IPO Close Date | 10 Dec 2025 |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹1008 to ₹1062 Per Share |
| Issue Size | Approx ₹655.37 Crores |
| Fresh Issue | - |
| Offer for Sale | Approx 61,71,101 Equity Shares |
| Issue Type | Book Built Issue |
| Listing On | BSE, NSE |
Corona Remedies IPO Review & Key Points
May Apply
Corona Remedies IPO Market Lot
The Corona Remedies IPO minimum market lot is 14 shares with ₹14,868 application amount. The retail investors can apply up-to 13 lots with 182 shares of ₹1,93,284 amount.
| Category | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 14 | ₹14,868 |
| Retail Maximum | 13 | 182 | ₹1,93,284 |
| S-HNI Minimum | 14 | 196 | ₹2,08,152 |
| S-HNI Maximum | 67 | 938 | ₹9,96,156 |
| B-HNI Minimum | 68 | 952 | ₹10,11,024 |
Corona Remedies IPO Reservation
| Investor Category | Shares Offered | % of Issue |
|---|---|---|
| Anchor Investor | 18,34,804 Shares | 29.73% |
| QIB (Ex. Anchor) | 12,21,729 Shares | 19.80% |
| NII / HNI | 9,16,960 Shares | 14.86% |
| Retail | 21,39,573 Shares | 34.67% |
Anchor Bidding Date: 05 Dec 2025
Anchor Issue Size: 194.86 Cr.
30 Days Lock-in: 10 Jan 2026
90 Days Lock-in: 11 Mar 2027
Corona Remedies IPO Dates & Allotment
| IPO Opening Date | 08 Dec 2025 |
| IPO Closing Date | 10 Dec 2025 |
| Bidding Cutoff Time | 5 PM |
| Basis of Allotment | 11 Dec 2025 |
| Refunds Initiation | 12 Dec 2025 |
| Credit to Demat | 12 Dec 2025 |
| IPO Listing Date | 15 Dec 2025 |
Corona Remedies Ltd Financials
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2023 | ₹891.10 | ₹756.07 | ₹84.93 | ₹595.02 |
| 2023 | ₹1,020.93 | ₹859.74 | ₹90.50 | ₹830.58 |
| 2024 | ₹1,202.35 | ₹956.44 | ₹149.43 | ₹929.86 |
| June 2025 | ₹348.56 | ₹276.76 | ₹46.20 | ₹1,012.38 |
Corona Remedies IPO Valuation
Check Corona Remedies IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| Parameter | Value |
|---|---|
| Earnings Per Share (EPS) | ₹24.43 (Basic) |
| P/E Ratio | N/A |
| Return on Equity (ROE) | 27.50% |
| Return on Capital Employed (ROCE) | 41.32% |
| Return on Net Worth (RoNW) | 24.65% |
| Net Asset Value (NAV) | ₹99.14 |
| EBITDA Margin | 20.55% |
| PAT Margin | 12.49% |
| Debt to Equity Ratio | – |
Corona Remedies IPO Peer Group Comparison
| Company | EPS | P/E | RoNW % | NAV | Total Income |
|---|---|---|---|---|---|
| Abbott India Limited | 665.62 | 54.28 | 33.41% | 1,992.14 | 6,409.15 Cr. |
| Alkem Laboratories Limited | 181.11 | 32.96 | 18.07% | 1,002.37 | 12,964.52 Cr. |
| Eris Lifesciences Limited | 25.85 | 47.99 | 12.21% | 209.73 | 2,893.64 Cr. |
| GlaxoSmithKline Pharmaceuticals Limited | 54.76 | 83.53 | 47.54% | 115.19 | 3,749.21 Cr. |
| J.B. Chemicals & Pharmaceuticals Limited | 42.45 | 47.21 | 19.21% | 220.88 | 3,917.99 Cr. |
| Mankind Pharma Limited | 49.28 | 54.17 | 13.89% | 352.51 | 12,207.44 Cr. |
| Pfizer Limited | 167.79 | 34.56 | 18.20% | 921.88 | 2,281.35 Cr. |
| Sanofi India Limited | 179.46 | 23.76 | 48.05% | 373.68 | 2,013.20 Cr. |
| Torrent Pharmaceuticals Limited | 56.47 | 66.51 | 25.18% | 224.28 | 11,516.09 Cr. |
Corona Remedies IPO Promoters & Holding Pattern
The promoters of the company are Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta and Ankur Kirtikumar Mehta.
| Particulars | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 6,11,60,088 | 72.50% |
| Promoter Holding Post Issue | 6,11,60,088 | -% |
Corona Remedies IPO Lead Managers (Merchant Bankers)
- JM Financial Ltd.
- IIFL Capital Services Ltd.
- Kotak Mahindra Capital Co. Ltd.
About Corona Remedies Ltd
Corona Remedies is an Indian pharmaceutical company that develops, manufactures, and markets a broad range of drug formulations across various therapeutic areas, with a key focus on women's healthcare, cardio-diabetes, pain management, and urology. The company is among the top 40 pharmaceutical companies in India.
Corona Remedies Ltd Address
Ahmedabad, Gujarat, 380059Phone: +91 79 4023 3000
Corona Remedies IPO Registrar
Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: [email protected]
Website: https://ipo.bigshareonline.com/IPO_Status.html